CTOs on the Move

Taro Pharmaceuticals (HQ)

www.tarousa.com

 
"Taro Pharmaceuticals U.S.A., Inc., and its divisions, subsidiaries and affiliates (collectively, ""Taro"") operate a variety of websites designed to provide you with services ranging from valuable health resources to corporate news and product information"
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.tarousa.com
  • 3 Skyline Dr Ste 120
    Hawthorne, NY USA 10532
  • Phone: 914.345.9001

Executives

Name Title Contact Details

Similar Companies

OptumRx

Optum is a health services and innovation company on a mission to help make the health system work better for everyone. We combine data and analytics with technology and expertise to power modern health care.

Walking Fish Therapeutics

Walking Fish Therapeutics, Inc. is a privately held biotechnology company discovering and developing innovative therapeutics that harness the power of B cells as protein factories and immune modulators. Walking Fish has created a broad technology platform addressing enzyme replacement therapies, oncology, autoimmune disease, and recombinant antibody production. The company`s first program, WFX-001, employs B cells as protein factories to generate a deficient enzyme in Fabry disease. Founded in 2019 by Lewis (Rusty) Williams, MD, PhD, the former CSO of Chiron, co-founder of Cor Therapeutics and founder and Chief Executive Officer of Five Prime Therapeutics, the company has assembled a diverse and experienced team of scientists and business leaders who are committed to bringing life-changing and life-saving therapeutics to patients worldwide.

Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT) is a private clinical stage biotechnology company headquartered in Rockville, MD. ICT is focused on the development of cellular immunotherapies for the treatment of solid tumors. ICT`s unique CoupledCAR® technology platform is designed to overcome the common challenges of treating solid tumors. ICT has achieved promising preclinical and proof-of-concept clinical results in late-stage solid tumors, such as colorectal cancer and thyroid cancer. The U.S. Food and Drug Administration (FDA) has provided a Study-May-Proceed letter for the Company`s Investigational New Drug (IND) application for a Phase 1 clinical trial of GCC19CART targeting relapsed and refractory metastatic colorectal cancer. ICT expects to initiate this U.S. focused clinical trial, referred to as CARAPIA-1, in the summer of 2022. The Company has a broad pipeline of CAR-T candidates targeting additional solid tumors.

Affinium Pharmaceuticals

Affinium Pharmaceuticals , Inc. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.